HomeCompareSUZRY vs PFE

SUZRY vs PFE: Dividend Comparison 2026

SUZRY yields 7.82% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SUZRY wins by $89212.83M in total portfolio value
10 years
SUZRY
SUZRY
● Live price
7.82%
Share price
$13.18
Annual div
$1.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$89212.88M
Annual income
$87,074,857,214.38
Full SUZRY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SUZRY vs PFE

📍 SUZRY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSUZRYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SUZRY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SUZRY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SUZRY
Annual income on $10K today (after 15% tax)
$665.03/yr
After 10yr DRIP, annual income (after tax)
$74,013,628,632.22/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SUZRY beats the other by $74,013,606,312.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SUZRY + PFE for your $10,000?

SUZRY: 50%PFE: 50%
100% PFE50/50100% SUZRY
Portfolio after 10yr
$44606.46M
Annual income
$43,537,441,736.55/yr
Blended yield
97.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SUZRY
No analyst data
Altman Z
3.4
Piotroski
9/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SUZRY buys
0
PFE buys
0
No recent congressional trades found for SUZRY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSUZRYPFE
Forward yield7.82%6.13%
Annual dividend / share$1.03$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$89212.88M$49.6K
Annual income after 10y$87,074,857,214.38$26,258.71
Total dividends collected$89066.76M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SUZRY vs PFE ($10,000, DRIP)

YearSUZRY PortfolioSUZRY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,265$1,564.76$9,153$693.39+$3.1KSUZRY
2$16,710$3,587.19$8,593$849.25+$8.1KSUZRY
3$27,016$9,135.47$8,336$1,066.78+$18.7KSUZRY
4$56,513$27,606.02$8,437$1,384.80+$48.1KSUZRY
5$168,408$107,939.60$9,013$1,875.40+$159.4KSUZRY
6$781,431$601,234.17$10,306$2,680.72+$771.1KSUZRY
7$6,050,684$5,214,552.42$12,820$4,101.38+$6.04MSUZRY
8$81,944,699$75,470,467.29$17,673$6,826.70+$81.93MSUZRY
9$1,998,148,414$1,910,467,586.02$27,543$12,591.86+$1998.12MSUZRY
10$89,212,876,017$87,074,857,214.38$49,560$26,258.71+$89212.83MSUZRY

SUZRY vs PFE: Complete Analysis 2026

SUZRYStock

Sulzer Ltd provides fluid engineering services. The company operates through Flow Equipment, Services, Chemtech, and Others segments. It offers side-mounted horizontal and top-mounted vertical agitators, dynamic chemical mixers, and tower and tank flow management products; tower management systems; turbo compressors, aeration systems, and mechanical aerators; cartridges, mixers, dispensers, and accessories; process solutions, which include the initial concept and pilot testing; medium consistency products; pumping solutions and auxiliary equipment; and control and monitoring equipment. The company also provides lifting stations; pump and lifting station accessories; products for distillation, absorption, stripping, evaporation, phase separation, liquid-liquid extraction, and crystallization; static and submersible mixers; solids reduction, separation, and removal systems; and screening, sedimentation, and filtration solutions. In addition, its services include rotating equipment services; static equipment services, welding, plant maintenance, and turnaround project services. Further, the company digital solution, which includes control and monitoring software solutions that include a range of software primarily designed to simplify set-up and maintenance for web-based alarm handling and monitoring software; sense condition monitoring solutions, which detects possible equipment failures early on and optimizes maintenance planning.; PumpsOnline services that allow access to equipment-related information; BLUE BOX, a collaborative digital solution; and DOC BOX, which allows users to systematically identify the root cause of a problem. It serves oil and gas; chemical; general industry; water; power; adhesive, dental, and healthcare; and beauty markets. The company operates in Switzerland, the United Kingdom, Saudi Arabia, Germany, Spain, Sweden, the Americas, and the Asia Pacific. Sulzer Ltd was founded in 1834 and is headquartered in Winterthur, Switzerland.

Full SUZRY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SUZRY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SUZRY vs SCHDSUZRY vs JEPISUZRY vs OSUZRY vs KOSUZRY vs MAINSUZRY vs JNJSUZRY vs MRKSUZRY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.